Institution: Distrust of the US dollar is driving gold and Bitcoin up

Whales aren’t selling even as BTC hits records — Bitcoin price prediction reveals why long-term holders still see upside ahead.

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…

PANews reported on October 9 that according to MLM monitoring, a Hyperliquid whale wallet closed out a HYPE long order worth $16 million and sold 100,000 HYPE (about $4.4 million) about 11 hours ago. The reason seems to be that its private key was leaked, resulting in the account being completely emptied: about $17 million in funds were stolen from its Hyperliquid account; another $3.1 million in assets deposited in the Plasma Syrup Vault (liquidity pool) were also stolen. After the attack, the hacker transferred all stolen assets, exchanging the stolen USDC for DAI and transferring it to two new wallets, where the funds are currently stored: The hacker also transferred MSYRUPUSDP worth $3.11 million to another new wallet.